GXI: Probe, Radiofrequency Lesion
What it covers
A radiofrequency lesion probe is a device connected to a radiofrequency (RF) lesion generator to deliver the RF energy to the site within the nervous system where a lesion is desired.
The identification in 21 CFR 882.4725, radiofrequency lesion probe. FDA gives GXI no definition of its own, so the regulation’s describes it.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K253907 | Disposable Radiofrequency Cannula | ABBOTT MEDICAL | Apr 16, 2026 | Traditional |
| K251802 | STAR RF Ablation System | Merit Medical Systems, Inc. | Feb 13, 2026 | Traditional |
| K251243 | OneRF Trigeminal Nerve Radiofrequency Probes | Neuroone Medical Technologies Corp. | Aug 15, 2025 | Traditional |
| K242841 | Disposable RF Electrode (RFDE-5/RFDE-10/RFDE-15/RFDE-20) | ABBOTT MEDICAL | May 27, 2025 | Traditional |
| K250213 | OptaBlate BVN Intraosseous Nerve Ablation System (10mm Probe Single Kit); OptaBlate BVN Intraosseous Nerve Ablation System (10mm Probe Dual Kit) | Stryker Instruments | May 15, 2025 | Traditional |
| K241367 | RF Cannula | Shanghai Samedical & Plastic Instruments Co., Ltd. | Jan 23, 2025 | Traditional |
| K222281 | Intracept Intraosseous Nerve Ablation System | Relievant Medsystems, Inc. | Oct 26, 2022 | Traditional |
| K213836 | Intracept Intraosseous Nerve Ablation System | Relievant Medsystems, Inc. | Mar 11, 2022 | Traditional |
| K203066 | COOLIEF Cooled Radiofrequency Kit Advanced | Avanos Medical, Inc. | Dec 22, 2020 | Traditional |
| K190259 | Vesta RF Cannula | Biomerics | Feb 7, 2020 | Special |
Clearances by year
28 GXI 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 2 | 189 |
| 2025 | 4 | 183 |
| 2022 | 2 | 91 |
| 2020 | 3 | 255 |
| 2019 | 3 | 63 |
| 2018 | 1 | 214 |
| 2017 | 3 | 125 |
| 2016 | 3 | 240 |
| 2015 | 1 | 167 |
| 2014 | 1 | 200 |
| 2013 | 1 | 170 |
| 2012 | 1 | 95 |
| 2011 | 3 | 64 |
Who submits
15 applicants cleared a GXI device since 2011. 68% of the clearances went to applicants in United States, then Canada (18%) and China (14%). By type: Traditional 86% and Special 14%. 5 went through a third-party review organization.
| Applicant | Clearances since 2011 |
|---|---|
| Diros Technology, Inc. | 5 |
| Relievant Medsystems | 4 |
| Lccs Products Limited | 3 |
| ABBOTT MEDICAL | 2 |
| Biomerics | 2 |
| Halyard Health, Inc. | 2 |
| Relievant Medsystems, Inc. | 2 |
| Avanos Medical, Inc. | 1 |
How FDA classifies it
Class II (performance standards).
From 21 CFR 882.4725.
Standards
21 CFR 882.4725 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent GXI clearances declared.
Ask about GXI
Questions about GXI
What is FDA product code GXI?
Product code GXI, “Probe, Radiofrequency Lesion” in FDA's classification database, is a Class II device type under 21 CFR 882.4725 (radiofrequency lesion probe), reviewed by FDA's Neurology panel. FDA's 510(k) database lists 66 clearances under GXI, 28 of them since 2011.
How many 510(k) clearances are there under GXI?
FDA’s 510(k) database listed 66 clearances under GXI as of Oct 29, 2026, 28 of them decided since 2011; the most recent decision was Apr 16, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a GXI 510(k)?
For the 6 GXI clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 189 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most GXI clearances?
Since 2011: Diros Technology, Inc. (5), Relievant Medsystems (4), Lccs Products Limited (3), ABBOTT MEDICAL (2) and Biomerics (2). 15 applicants have cleared a GXI device in that time.